SAB Biotherapeutics, Inc. (SABSW) stock
SABSWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABS
$0.01+0.00 (+33.33%)
Close on Oct 20, 2026Market cap $304.80MP/E –Yield –
SAB Biotherapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
SAB Biotherapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$53.94M. For fiscal 2025 it was -$44.78M. The highest annual figure on record is $10.00M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$44.78M | – |
| FY2024 | Dec 31, 2024 | -$34.29M | – |
| FY2023 | Dec 31, 2023 | -$25.12M | – |
| FY2022 | Dec 31, 2022 | -$23.46M | -1280.7% |
| FY2021 | Dec 31, 2021 | $1.99M | -80.1% |
| FY2020 | Dec 31, 2020 | $10.00M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$9.84M | – |
| Q1 FY2026 | Mar 31, 2026 | -$14.27M | – |
| Q4 FY2025 | Dec 31, 2025 | -$16.78M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.05M | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.15M | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.80M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.53M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.29M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.72M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.75M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.45M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.17M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.90M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.61M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.56M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.92M | -308.5% |
| Q2 FY2022 | Jun 30, 2022 | -$4.45M | – |
| Q1 FY2022 | Mar 31, 2022 | -$9.54M | -200.9% |
| Q4 FY2021 | Dec 31, 2021 | -$4.88M | – |
| Q3 FY2021 | Sep 30, 2021 | $3.80M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.39M | – |
| Q1 FY2021 | Mar 31, 2021 | $9.45M | – |